Novartis’ Foradil Should Add “Black Box” Warning About Potential Class Effect In Asthmatics
This article was originally published in The Pink Sheet Daily
Executive Summary
Boxed warning should explain that increases in asthma-related deaths have been seen in studies of related agent salmeterol (GSK’s Serevent and Advair) and the risk could extend to Foradil (formoterol), advisory committee says. Continued marketing of Serevent, Advair and Foradil supported by the panel.
You may also be interested in...
Long-Acting Beta Agonists Revised Labeling Warns Of Asthma Death Potential
FDA issues revised labeling for GlaxoSmithKline’s Serevent, Advair, but continues to negotiate changes to Novartis/Schering’s Foradil.
Long-Acting Beta Agonists Revised Labeling Warns Of Asthma Death Potential
FDA issues revised labeling for GlaxoSmithKline’s Serevent, Advair, but continues to negotiate changes to Novartis/Schering’s Foradil.
Serevent, Advair, Foradil Relegated To Second-Line For Asthma Patients
FDA Public Health Advisory says long-acting beta agonist bronchodilators “should be added to the asthma treatment plan only if other medicines do not control asthma.”